Navigation Links
Green Tea Component May Slow Prostate Cancer
Date:6/19/2009

Men in small study took capsules equivalent to brewed beverage,,

FRIDAY, June 19 (HealthDay News) -- The active compounds in green tea might slow the progression of prostate cancer, the results of a small study suggest.

The study included 26 men, 41 to 72 years old, who had prostate cancer and were scheduled for radical prostatectomy. The men took four capsules a day of an investigational agent called Polyphenon E, an amount equivalent to about 12 cups of normally brewed, concentrated green tea. The men took the capsules for 12 to 73 days, with a median time of 34.5 days, but stopped the day before surgery.

The phase 2 study found "significant" reductions in the men's serum levels of markers predictive of prostate cancer progression, including hepatocyte growth factor, vascular endothelial growth factor and prostate specific antigen. In some men, reductions in levels of these markers were greater than 30 percent, the researchers found.

There were few reported side effects, and the men's liver function remained normal, according to James A. Cardelli, a professor and director of basic and translational research at the Feist-Weiller Cancer Center at Louisiana State University Health Sciences Center-Shreveport, and his research colleagues. The findings are reported in Cancer Prevention Research.

A recent year-long clinical trial in Italy found that consumption of green tea polyphenols reduced prostate cancer risk in men with high-grade prostate intraepithelial neoplasia, according to a news release from the American Association for Cancer Research.

"These studies are just the beginning, and a lot of work remains to be done," Cardelli said in the news release. "However, we think that the use of tea polyphenols alone or in combination with other compounds currently used for cancer therapy should be explored as an approach to prevent cancer progression and recurrence."

More informa
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Clearly Contacts Goes Green With Organic Glasses
2. University HealthSystem Consortium Selected as Greenville Hospital Systems Supply Chain Partner
3. Pacific Shore Holdings, Inc. Launches Burner Balm a Revolutionary, Energy-Boosting, Appetite-Suppressing, Fat-Burning Lip Balm - Natural, Green and Cost-Effective - Featured on NBCs Today Show
4. Morning Sickness Drug Gets Green Light in Study
5. Biopolymers Symposium 2009 Announces Final Program and Interactive Green Brochure
6. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
7. Green Family Foundation Gives $10 Million Boost to FIU Community Medicine Program
8. JOIN Funding Collaborative Connects Philadelphia Workers to Living-Wage Green, Healthcare Jobs
9. NXGen Holdings, Inc. Enters the $17.5 Billion Household and Industrial Cleaning Products Industry through the Acquisition of Green Bridge Industries, Inc.
10. Greenway Medical Technologies PrimePatient Solution Transforms Physician/Patient Relationship Through Enhanced Communication Channels and Improved Workflows
11. Consorta Receives Practice Greenhealth Champion for Change Award for Sixth Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Green Tea Component May Slow Prostate Cancer 
Green Tea Component May Slow Prostate Cancer
Breaking Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 1Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 1CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 3Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 1Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 2